On Chemball
My Chemball
+86-571-8627 3270
Shanghai Jinhe BIO-PHARMACEUTICAL Co., Ltd.
Shanghai Jinhe BIO-PHARMACEUTICAL Co., Ltd.
22 YRS
Shanghai, China
Main Products:
Paclitaxel / Docetaxel / Docetaxel Trihydrate / Cabazitaxel / 10-Deacetylbaccatin III / Baccatine III
Shanghai, China
Send Email
Sending...
Thank You！
Your requirement has been sent, we will contact you quickly!
Sent Failed！
Try again!
ABOUT US
Shanghai Jinhe bio-pharmaceutical Co., Ltd. is a pharmaceutical enterprise specializing in the research, production and sales of antitumor APIs and intermediates. Founded in March 2002, based on the scientific research achievements of Fudan University, the company began to undertake the international paclitaxel API processing business. After several years of hard work, the company has successfully developed paclitaxel, docetaxel, irinotecan, etoposide and other products, from naturally extracted antitumor drugs to plant-derived antitumor drug raw materials. In the past two years, the company has developed carbataxel, palonosetron hydrochloride and other products. In 2012, the company signed a contract with Shanghai Zhongxi Sanwei Pharmaceutical Co., Ltd., a subsidiary of Shanghai Pharmaceutical Group. Since then, Jinhe biology has been positioned as the production base of antitumor API of Shanghai Pharmaceutical Group. In 2015, the company and Shanghai Huayu Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Shanghai pharmaceutical, invested in the reorganization of Dali Zhonggu yew biological Co., Ltd. (now renamed Shanghai Pharmaceutical Group (DALI) yew biological Co., Ltd.) in cash to integrate Shanghai Pharmaceutical antitumor drug industry chain and establish API advantages. In January 2017, the company successfully passed the GMP certification of API (paclitaxel, docetaxel). Jinhe has always been committed to being a responsible and responsible pharmaceutical enterprise with leading position in China, significant international influence and responsibility.
Basic Information
Tax ID
91310118736688258F
Country/Region
Shanghai, China
Year Established
2002
Registered Capital
CNY 3.4 Million
Business Type
Manufacturing
Total Employees
100-500 people
Quality Management Certificate
ISO9001
Total Annual Revenue
-
Enterprise Ownership
Private Owned
Is This Your Own Factory
Yes
Summary Up
The company has successfully developed paclitaxel, docetaxel, irinotecan, etoposide and other products, and developed from naturally extracted antitumor drugs to plant derived antitumor drug raw materials
PLANT LOCATION
ORGANIZATION UNIT
18 People
R&D Dept
COMPANY ALBUM
){kind=link}
){kind=link}